Adirondack Trust Company’s ImmunityBio IBRX Stock Holding History

Adirondack Trust Company’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-150	Closed	-$297	–	554
2025 Q4	$297	Hold	150	–	–	﹤0.01%	527
2025 Q3	$369	Hold	150	–	–	﹤0.01%	502
2025 Q2	$394	Hold	150	–	–	﹤0.01%	472
2025 Q1	$450	Hold	150	–	–	﹤0.01%	468
2024 Q4	$382	Hold	150	–	–	﹤0.01%	476
2024 Q3	$558	Sell	150 -300	-67%	-$1.39K	﹤0.01%	478
2024 Q2	$2.84K	Hold	450	–	–	﹤0.01%	440
2024 Q1	$2.42K	Hold	450	–	–	﹤0.01%	459
2023 Q4	$2.13K	Hold	450	–	–	﹤0.01%	461
2023 Q3	$760	Hold	450	–	–	﹤0.01%	474
2023 Q2	$990	Hold	450	–	–	﹤0.01%	450
2023 Q1	$814	Hold	450	–	–	﹤0.01%	472
2022 Q4	$2.28K	Hold	450	–	–	﹤0.01%	439
2022 Q3	$2K	Buy	450 +150	+50%	+$684	﹤0.01%	443
2022 Q2	$1K	Buy	+300	New	+$1.21K	﹤0.01%	441

Other funds holding IBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Adirondack Trust Company's IBRX Position: Q1 2026 in Review

Adirondack Trust Company sold out of ImmunityBio (IBRX) in Q1 2026, closing a stake of 150 shares — an estimated $297 sold.

Adirondack Trust Company first reported a position in IBRX in Q2 2022 and held it in 15 quarters. The position peaked at $2.84K in Q2 2024. 386 funds tracked by Wall St. Rank hold IBRX as of Q1 2026.

Adirondack Trust Company reported no remaining ImmunityBio position as of Q1 2026 after selling out during the quarter.
Adirondack Trust Company sold 150 ImmunityBio shares in Q1 2026, an estimated $297.
Adirondack Trust Company first reported a position in ImmunityBio in Q2 2022 and held it in 15 quarters.
Adirondack Trust Company's ImmunityBio position peaked at $2.84K in Q2 2024.
386 funds tracked by Wall St. Rank held ImmunityBio as of Q1 2026.

Based on Adirondack Trust Company's 13F filing for Q1 2026, filed 3 Apr 2026.